Key result
Naftidrofuryl at therapeutic concentrations inhibited platelet activation induced by ET-1 alone and in combination with ADP or serotonin in human platelets.
Why the study?
Does naftidrofuryl inhibit endothelin-1 induced platelet activation in human platelets?
Does naftidrofuryl inhibit endothelin-1 induced platelet activation in human platelets?
Naftidrofuryl antagonizes endothelin-1 induced platelet activation, which may contribute to its beneficial effects in peripheral vascular disease.
Answers are grounded in this paper and cite their sources.
Naftidrofuryl may benefit peripheral vascular disease via ET-1 inhibition; leaves open clinical translation and requires prospective trials.
Naftidrofuryl (Praxilene; NAF) significantly improves claudication distance in patients with peripheral vascular disease (PVD). Endothelin-1 (ET-1) is a powerful endogenous vasoconstrictor and the circulating levels of ET-1 are elevated in patients with vascular disease. Platelet rich plasma (PRP) was prepared from healthy volunteers. NAF at concentrations similar to therapeutic levels (3.5-14 micromol/l), inhibited (P < 0.02) platelet activation (as indicated by a fall in median platelet volume, MPV) induced by ET-1 (0.4 micromol/l) alone. NAF also inhibited (P <0.0001) shape change (PSC; an early phase of platelet activation, characterised by an increase in MPV) induced by ET-1 (0.4 micromol/l) in combination with ADP (0.05-0.15 micromol/l) or serotonin (0.03-0.13 micromol/ l). We assessed the effect of ET(A) (BQ123, 50 nmol/l) or ET(B) (BQ788, 50 nmol/l) receptor antagonists on PSC induced by ET-1 alone. Both antagonists significantly inhibited PSC. We conclude that ET-1 activates human platelets. Both ET(A) and ET(B) receptors probably contribute to this response by a complex mechanism that requires further elucidation. NAF antagonises the action of ET-1 on human platelets. These actions may contribute to the beneficial effects of NAF in PVD.
No takes yet. Share an insight, caveat, or question.
D. P. Mikhailidis I. A. Jagroop (2000) studied Healthy volunteers. Naftidrofuryl (NAF) vs. Endothelin-1 (ET-1) alone was evaluated on Platelet activation (fall in median platelet volume) induced by ET-1 (p=<0.02). Naftidrofuryl at therapeutic concentrations inhibited platelet activation induced by ET-1 alone and in combination with ADP or serotonin in human platelets.
Synapse has enriched 10 related papers. Consider them for comparative context: